Universal Donor Stem Cells
Universal Donor Stem Cells - Related Videos
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
0 Views •
Cited by 2 •
2017
Quantification of donor-derived cells is required to monitor engraftment after stem cell transplantation in patients with hemoglobinopathies. A combination of flow cytometry-based cell sorting, colony formation assay, and subsequent analysis of short tandem repeats may be used to assess the proliferation and differentiation of progenitors in the erythroid compartment.
22:06
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
0 Views •
Cited by 7 •
2007
This protocol details the derivation of transplantable hematopoietic stem cells from mouse embryonic stem cells (ESC) and their subsequent injection into lethally irradiated recipient mice. Briefly, ESC are differentiated as embryoid bodies, which are then infected with retroviral HoxB4 and co-cultured with OP9 stromal cells and hematopoietic cytokines.
07:49
Isolating Stem Cells from Soft Musculoskeletal Tissues
0 Views •
Cited by 21 •
2010
Isolating adult stem cells from musculoskeletal soft tissues based on the cell's adherence speed to flask.
08:32
Preparation of Pooled Human Platelet Lysate (pHPL) as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
0 Views •
Cited by 133 •
2009
Human platelet lysate is a rich source of growth factors and a potent supplement in cell culture. This protocol presents the process of preparing a large pool of human platelet lysate by starting from platelet rich plasma, performing several freeze-thaw cycles and depleting the platelet fragments.
20:38
Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)
0 Views •
Cited by 31 •
2007
FAQs
Targeted gene editing can reduce or alter human leukocyte antigen display on the stem-cell surface. Because recipient T cells use these molecules to identify cellular targets, changing their display may lessen immune recognition after transplantation. The design therefore focuses not only on producing compatible cells, but also on modifying the specific interaction that initiates T-cell-mediated rejection.
Reducing human leukocyte antigen display may decrease recognition by recipient T cells, but it can also create a different immune concern: natural killer cells may respond when expected surface signals are missing or altered. Effective designs must therefore balance these opposing risks. This requirement makes immune compatibility a multi-component problem rather than a single gene-editing target.
T-cell recognition and natural killer cell activity do not represent the entire compatibility challenge. The overview also identifies other immune defenses that may respond to engineered cells. Consequently, a candidate design cannot be judged solely by reduced human leukocyte antigen display. Its broader immune behavior must be considered when developing cells for broadly usable therapies.
Researchers begin with stem cells that can be engineered or selected for broader recipient compatibility, then focus on human leukocyte antigen display as a principal design variable. Targeted gene editing may reduce or alter that display, while the resulting design must be considered for T-cell recognition, natural killer cell activation, and other immune defenses before application.
In developmental biology, Universal Donor Stem Cells can provide standardized material for examining differentiation and tissue formation. Using a more consistent cellular starting point may help researchers compare developmental outcomes across experiments and investigate disease mechanisms. This role connects immune-compatibility engineering with fundamental questions about how stem cells produce specialized cells and organized tissues.
Their potential compatibility with many recipients could make them useful starting material for organoid research and regenerative medicine. Standardized cells may support repeatable studies of tissue development, disease mechanisms, and therapeutic cell production. If broadly usable designs succeed, they could simplify manufacturing, improve treatment access, and help move stem-cell findings toward clinical applications.